Health Company Receives FDA Approval For Obesity Drug Study
A Revolutionary Step in Obesity Management: The Approval of Fractyl Health's Revita® Remain-1 Study.
In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With obesity being a major health concern worldwide, this news could potentially change the lives of millions. $Fractyl Health(GUTS.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
